Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Safety, pharmacodynamics (PD) and pharmacokinetics (PK) of darotropium (DARO) and vilanterol (VI) in healthy subjects: Two phase 1 studies Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy at two UMEC doses in healthy subjects Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014
Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy in healthy subjects Source: International Congress 2014 – Asthma and COPD management Year: 2014
The pharmacokinetics (PK) and pharmacodynamics (PD) of the fluticasone furoate (FF) and vilanterol (VI) combination in subjects with severe renal impairment Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
The pharmacokinetics (PK) and pharmacodynamics (PD) of the fluticasone furoate (FF) and vilanterol (VI) combination in subjects with hepatic impairment Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Evaluating lung function response to umeclidinium/vilanterol (UMEC/VI) 62.5/25mcg, UMEC 62.5mcg and VI 25mcg in COPD patients Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single (SD) and repeat (RD) inhaled doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered to healthy smokers Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
Pharmacokinetic (PK) interaction of ketoconazole (KC), clarithromycin (CM) and midazolam (MZ) with riociguat Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
The effect of ketoconazole on the pharmacokinetics (PK) and pharmacodynamics (PD) of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
LATE-BREAKING ABSTRACT: Single-dose safety, tolerability, PD & PK of AZD8999, a bi-functional muscarinic antagonist/β2-agonist (MABA), in patients with COPD Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
Dose-related efficacy of vilanterol trifenatate (VI), a long-acting beta2 agonist (LABA) with inherent 24-hour activity, in patients with persistent asthma Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (320/9mcg) Spiromax® and BF (400/12mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (160/4.5mcg) Spiromax® and BF (200/6mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013
Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Dose-related efficacy of vilanterol trifenatate (VI) in COPD Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
Integrated analyses of phase II safety data support the safety of glycopyrrolate-formoterol fumarate (GFF) MDI (PT003) and glycopyrrolate (GP) MDI (PT001) in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Onset of action of aclidinium (ACL), glycopyrronium (GLY) and tiotropium (TIO): A comparison in COPD patients Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Pharmacokinetics (PK) and pharmacodynamics (PD) of tetomilast in stable COPD subjects Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006